Maruho Broadens Derma Horizons Through Dual Licensing Deals
Derma specialist Maruho has taken steps to recharge its pipeline through deals with fellow Japanese firms for two novel assets.
You may also be interested in...
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.
Results from a large Swedish study provide further evidence that mixing different COVID-19 vaccines boosts effectiveness. Meanwhile, Japan plans new funding to support the home-grown development of coronavirus and other vaccines.